Primary Large-cell Neuroendocrine Tumor of the Breast

2013 ◽  
Vol 19 (2) ◽  
pp. 204-206 ◽  
Author(s):  
Marcelino Yazbek Hanna ◽  
Edmund Leung ◽  
Colin Rogers ◽  
Simon Pilgrim
2019 ◽  
Vol 27 (8) ◽  
pp. 893-899
Author(s):  
Laura G. Pastrián ◽  
Ignacio Ruz-Caracuel ◽  
Raul S. Gonzalez

Primary neuroendocrine neoplasms of the liver have occasionally been reported in the liver, though many reports do not convincingly exclude metastases. In this article, we report 2 “giant” hepatic neuroendocrine lesions without evidence of a primary elsewhere after clinical workup. One occurred in a 21-year-old male; the lesion was a large cell neuroendocrine carcinoma measuring 24 cm. The patient died of disease in 10 months. The other occurred in a 25-year-old patient, was 18 cm wide, and was diagnosed as a well-differentiated neuroendocrine tumor, World Health Organization grade 3. The patient died of disease after 30 months. Molecular testing demonstrated only the presence of TP53 mutations in common. These cases expand our knowledge of seemingly primary neuroendocrine neoplasms of the liver, in particular, giant cases measuring more than 8 cm. Guidelines for clinical workup and therapy for these lesions remain unclear, but future thorough workup of such cases is necessary for specific characterization.


HPB ◽  
2018 ◽  
Vol 20 ◽  
pp. S699-S700
Author(s):  
S.K. Pimentel ◽  
C. Popovicz ◽  
P.A. De Almeida ◽  
D.G. Sakamoto ◽  
R.M. Azevedo ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Katherine Dowd ◽  
Charles Rotenberry ◽  
Douglas Russell ◽  
Mitchell Wachtel ◽  
Werner de Riese

Neuroendocrine tumors rarely occur in the urinary bladder. They can be carcinomatous, subdivided into small cell and large cell pathology. Small cell carcinoma of the bladder is a rarity that may present at an advanced pathologic stage. No treatment regimens have been standardized for local or metastatic disease. Review of the recent literature shows equivalent survival data for localized disease treated with chemoradiotherapy combined with either bladder sparing surgery or radical cystectomy. Patients with significant comorbidities are an additional challenge. We report a case of poorly differentiated neuroendocrine tumor of the bladder, which could not be classified as small or large cell carcinoma, complicated by significant comorbidities. After management with transurethral resection of the tumor, adjuvant chemotherapy, and radiation, the patient is alive and asymptomatic nearly 1 year after initial TURBT with no evidence of disease recurrence.


2019 ◽  
Vol 43 (7) ◽  
pp. 1712-1720 ◽  
Author(s):  
Maria Cattoni ◽  
Eric Vallières ◽  
Lisa M. Brown ◽  
Amir A. Sarkeshik ◽  
Stefano Margaritora ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Jean-Luc Raoul ◽  
Marie-Françoise Heymann ◽  
Frédéric Dumont ◽  
Alain Morel ◽  
Hélène Senellart ◽  
...  

Temporal and spatial tumor heterogeneity can be observed in pancreatic neuroendocrine tumor. We report the case of a young woman with long term stabilization of a G2 metastatic pancreatic NET that, after pregnancy, suddenly progressed into one single liver metastasis corresponding to a transformation into G3 large-cell neuroendocrine cancer. The patient underwent liver resection (the progressive and one dormant metastasis). With a 45 months follow-up the patient is without evolutive disease. Exome sequencing of the two metastases revealed completely different genomic signatures and gene alterations: the dormant metastasis was MSS without any gene alteration; the poorly differentiated tumor was MSI, with gain of many mutations including MEN1, BCL2, MLH1 and TP53 corresponding to a mutational signature 11. Could temozolomide play a role in this transformation?


2018 ◽  
Vol 8 (2) ◽  
Author(s):  
Sara Póvoa ◽  
Daniela Azevedo ◽  
Cristiana Marques ◽  
Helena Barroca ◽  
Andreia Costa

Sign in / Sign up

Export Citation Format

Share Document